Search results
Results from the WOW.Com Content Network
Schematic of the relation between an immunoglobulin and RAGE Schematic of the RAGE gene and its products. RAGE (receptor for advanced glycation endproducts), also called AGER, is a 35 kilodalton transmembrane receptor [5] of the immunoglobulin super family which was first characterized in 1992 by Neeper et al. [6] Its name comes from its ability to bind advanced glycation endproducts (), which ...
AGEs have specific cellular receptors; the best-characterized are those called RAGE. The activation of cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggers the generation of free radicals and the expression of inflammatory gene mediators. [28]
5891 26448 Ensembl ENSG00000080823 ENSMUSG00000056458 UniProt Q9UQ07 Q9WVS4 RefSeq (mRNA) NM_001272011 NM_014226 NM_001330234 NM_001353827 NM_001353828 NM_001353829 NM_001353830 NM_001353831 NM_001353832 NM_011973 RefSeq (protein) NP_001258940 NP_001317163 NP_055041 NP_001340756 NP_001340757 NP_001340758 NP_001340759 NP_001340760 NP_001340761 NP_036103 Location (UCSC) Chr 14: 102.22 – 102.31 ...
n/a Ensembl ENSG00000163221 n/a UniProt P80511 n/a RefSeq (mRNA) NM_005621 n/a RefSeq (protein) NP_005612 n/a Location (UCSC) Chr 1: 153.37 – 153.38 Mb n/a PubMed search n/a Wikidata View/Edit Human S100 calcium-binding protein A12 (S100A12) is a protein that in humans is encoded by the S100A12 gene. Human S100A12, also known as calgranulin C, was first described in 1995. The protein encoded ...
HMGB1 has to interact with p53. [15] [16]HMGB1 is a nuclear protein that binds to DNA and acts as an architectural chromatin-binding factor. It can also be released from cells, an extracellular form in which it may bind to toll-like receptors (TLRs) or an inflammatory receptor called the receptor for advanced glycation end-products RAGE.
Thus, free radical-mediated reperfusion injury was seen to contribute to the process of innate and subsequent adaptive immune responses. [ 9 ] The second study [ 10 ] suggested the possibility that the immune system detected "danger", through a series of what is now called damage-associated molecular pattern molecules (DAMPs), working in ...
This page was last edited on 19 September 2016, at 16:08 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Azeliragon (TTP488 or PF-04494700) is a small-molecule RAGE inhibitor. It is developed by vTv Therapeutics for various cancers, including triple-negative breast cancer, [1] [2] pancreatic cancer. [3] The chemical reached Phase III trials in slowing cognitive deterioration in early stage Alzheimer's disease patients.